CASC3 and glioblastoma: The response to BTZ was in contrast to a second proteasome inhibitor, carfilzomib, which was deemed unsuitable for further investigation because it required high doses, did not kill all GBM cell types, and/or killed the normal astrocytes more efficiently, thus limiting its potential therapeutic window.